Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodevelopmental and Neuropsychiatric Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GRIN2D drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GRIN2D ECD Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View GRIN2D Products |
| Gene Delivery | GRIN2D Lentivirus Premade Particles Full-length ORF for stable cell line construction and functional calcium flux/electrophysiology assays. |
View GRIN2D Products |
| Benchmark Ab | Anti-GRIN2D Recombinant Antibody Recombinant positive control for surface expression validation. |
View GRIN2D Products |
| Validator | GRIN2D siRNA Set For knockdown verification and target specificity validation. |
View GRIN2D Products |
| Related Target A | GRIN1 (GluN1) Essential co-agonist subunit required to form functional heteromeric NMDA receptor channels with GRIN2D. |
View GRIN1 Products |
| Related Target B | GRIN2B (GluN2B) Key subunit involved in subunit-selective screening to rule out off-target NMDA receptor modulation. |
View GRIN2B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent functional screening of complex ion channels | Lentivirus-mediated stable expression preserves native multi-pass transmembrane structure. |
| Subtype selectivity (avoiding GRIN2A/GRIN2B off-target effects) | Sequence-verified target panels (GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D) for strict counter-screening. |
| Lack of reliable positive controls | Sequence-verified biosimilar antibodies and validated positive controls included. |
| High rates of assay false positives | High-specificity siRNA validation tools included for target-specific knockdown verification. |
Live GRIN2D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GRIN2D therapeutics is intensifying, with major players shifting focus from non-selective NMDA modulators to highly selective positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs). As first-generation therapies for developmental and epileptic encephalopathy (DEE) enter clinical exploration, the next wave of R&D is targeting pediatric orphan indications, treatment-resistant depression, and schizophrenia. Precise modulation of the slow deactivation kinetics unique to GluN2D-containing receptors represents the primary engineering frontier.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (NAM) | Sage Therapeutics, Neuronalys | GRIN2D-related Epileptic Encephalopathy | Electrophysiology & Calcium Flux (Need Lentivirus for Stable Cell Line) |
| Small Molecule (PAM) | Cadent Therapeutics (Novartis), Academic Spin-offs | Schizophrenia, Cognitive Impairment | Subfamily Selectivity Screen (Need GRIN2A/B/C/D Homolog Panels) |
| Gene Therapy / RNAi | Exicure, Ionis Pharmaceuticals | Severe Neurodevelopmental Disorders | Target Knockdown Validation (Need High-specificity siRNA Sets) |